Research Ethics & Policy Series (REPS): Sickle Cell Gene Therapy - Alexis A. Thompson, MD, MPH

12:00pm - 1:00pm • Hybrid: RCH B102AB, Richards Bldg., 3700 Hamilton Walk (and virtual via Zoom)

2026-02-10 12:00:00 2026-02-10 13:00:00 America/New_York Research Ethics & Policy Series (REPS): Sickle Cell Gene Therapy - Alexis A. Thompson, MD, MPH Sickle Cell Gene Therapy Alexis A. Thompson, MD, MPH Professor of Pediatrics (Hematology) Chief, Division of Hematology Elias Schwartz MD Endowed Chair in Hematology Children's Hospital of Philadelphia Dr. Thompson has dedicated her career to advocating for bringing cutting-edge treatments and technology to sickle cell disease (SCD) patients locally and globally to help improve their quality of life. She brings hematological expertise as a member of CHOP’s Sickle Cell and Red Cell Disorders Curative Therapy Center (CuRED), which is one of a select group of treatment centers offering gene therapies to treat SCD. Her clinical research on the lentiviral vector therapy lovotibeglogene autotemcel for severe sickle cell disease also led to the approvals of the first two gene therapies for SCD. More detail to follow. Registration required; Lunch provided Streaming available via Zoom. Hybrid: RCH B102AB, Richards Bldg., 3700 Hamilton Walk (and virtual via Zoom) Penn Medical Ethics

Dr. Thompson has dedicated her career to advocating for bringing cutting-edge treatments and technology to sickle cell disease (SCD) patients locally and globally to help improve their quality of life. She brings hematological expertise as a member of CHOP’s Sickle Cell and Red Cell Disorders Curative Therapy Center (CuRED), which is one of a select group of treatment centers offering gene therapies to treat SCD. Her clinical research on the lentiviral vector therapy lovotibeglogene autotemcel for severe sickle cell disease also led to the approvals of the first two gene therapies for SCD.

More detail to follow.